UnknownNot Applicable

Early Diagnosis of Aspergillosis in Patients at High Risk of Fungal Infection Caused by Treatment for Hematologic Cancer or Other Disease

United Kingdom200 participantsStarted 2005-07

Plain-language summary

RATIONALE: Studying ways to diagnose fungal infections early may help doctors plan the best treatment. PURPOSE: This clinical trial is studying laboratory tests to see how well they find aspergillosis early in patients at high risk of fungal infection caused by treatment for hematologic cancer or other disease.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

DISEASE CHARACTERISTICS: * At high risk for developing invasive aspergillosis (IA) due to any of the following risk factors: * Diagnosis of acute myeloid leukemia, myelodysplastic syndromes, or acute lymphoblastic leukemia AND meets ≥ 1 of the following criteria: * Receiving intensive chemotherapy with expected duration of neutropenia (ANC \< 500/mm³) of \> 10 days * Receiving high-dose steroids * Concurrent treatment with allogeneic hematopoietic stem cell transplantation (HSCT) * Requirement for high-dose steroids for graft-versus-host disease after HSCT * History of probable or proven IA and receiving chemotherapy * No preexisting chest disease PATIENT CHARACTERISTICS: * Not specified PRIOR CONCURRENT THERAPY: * See Disease Characteristics

What they're measuring

Sensitivity and specificity of galactomannan (GM) ELISA and real time PCR in detecting invasive aspergillosis (IA)

Diagnostic value of IA screening by GM ELISA and real time PCR, in terms of positive and negative predicative values

Trial details

NCT IDNCT00462657

SponsorSt. Bartholomew's Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

View on ClinicalTrials.gov More Graft Versus Host Disease trials